Carisma Therapeutics, Inc. (CARM)
NASDAQ: CARM · Real-Time Price · USD
0.460
+0.004 (0.79%)
Feb 12, 2025, 4:18 PM EST - Market closed
Carisma Therapeutics Employees
Carisma Therapeutics had 107 employees as of December 31, 2023.
Employees
107
Change
n/a
Growth
n/a
Revenue / Employee
$189,421
Profits / Employee
-$596,262
Market Cap
19.21M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 107 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
CARM News
- 7 days ago - Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference - PRNewsWire
- 2 months ago - Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline - PRNewsWire
- 2 months ago - Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - PRNewsWire
- 3 months ago - Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 - PRNewsWire
- 3 months ago - Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma - PRNewsWire
- 3 months ago - Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - PRNewsWire
- 3 months ago - Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024 - PRNewsWire
- 3 months ago - Carisma Therapeutics Announces Changes to its Board of Directors - PRNewsWire